"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience.
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
07 12 2021
07 12 2021
Historique:
received:
26
09
2021
accepted:
17
11
2021
revised:
17
11
2021
entrez:
8
12
2021
pubmed:
9
12
2021
medline:
3
2
2022
Statut:
epublish
Résumé
Belantamab mafodotin is a highly selective targeted therapy for multiple myeloma. It targets the B cell maturation antigen (BCMA) on plasma cells and showed promising results in several randomized clinical trials. We report the outcomes of 36 patients treated at Mayo Clinic. Our cohort received a median of eight prior lines of therapy. Six patients received belantamab in combination with other medications (pomalidomide, cyclophosphamide, thalidomide), 13 patients (36%) were 70 years or older, two patients had a creatinine of >2.5 mg/dL, and one patient was on dialysis. All three patients with renal failure received full dose belantamab. Chimeric antigen receptor (CAR-T) therapy was used prior to belantamab in seven patients and none of them responded to belantamab therapy. The overall response rate (ORR) was 33% (CR 6%, VGPR 8%, PR 19%), like the ORR reported in the DREAMM-2 trial. Keratopathy developed in 16 patients (43%), grade 1 in six patients, grade 2 in seven patients, and grade 3 in three patients. Eight percent discontinued therapy due to keratopathy. The median PFS and OS was 2 months and 6.5 months, respectively.
Identifiants
pubmed: 34876555
doi: 10.1038/s41408-021-00592-3
pii: 10.1038/s41408-021-00592-3
pmc: PMC8651684
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
belantamab mafodotin
DB1041CXDG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
196Subventions
Organisme : NCI NIH HHS
ID : P50 CA186781
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
Front Oncol. 2021 May 11;11:678634
pubmed: 34046363
Mol Cancer Ther. 2021 Oct;20(10):1941-1955
pubmed: 34253590
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
N Engl J Med. 2021 Feb 25;384(8):705-716
pubmed: 33626253
Nat Commun. 2021 Feb 8;12(1):868
pubmed: 33558511
Proc Natl Acad Sci U S A. 2019 May 7;116(19):9543-9551
pubmed: 30988175
Nat Med. 2021 Apr;27(4):616-619
pubmed: 33619368
Br J Haematol. 2016 Sep;174(6):911-22
pubmed: 27313079
Lancet Oncol. 2020 Feb;21(2):207-221
pubmed: 31859245
Future Oncol. 2021 Jun;17(16):1987-2003
pubmed: 33682447
Cancer. 2021 Nov 15;127(22):4198-4212
pubmed: 34314018
Lancet. 2020 Jul 18;396(10245):186-197
pubmed: 32682484
Blood. 2014 May 15;123(20):3128-38
pubmed: 24569262
Lancet. 2021 Jul 24;398(10297):314-324
pubmed: 34175021
Eye Contact Lens. 2021 Jun 1;47(6):362-365
pubmed: 33306485
Blood Adv. 2019 Aug 27;3(16):2487-2490
pubmed: 31451444
Blood Cancer J. 2021 May 26;11(5):103
pubmed: 34039952
J Clin Oncol. 2020 Mar 10;38(8):775-783
pubmed: 31895611
Leukemia. 2019 Sep;33(9):2266-2275
pubmed: 30858549
Lancet. 2019 Dec 7;394(10214):2096-2107
pubmed: 31735560
Leuk Res. 2019 Jun;81:62-66
pubmed: 31035033
Nat Commun. 2015 Jun 11;6:7333
pubmed: 26065893
Lancet Oncol. 2018 Dec;19(12):1641-1653
pubmed: 30442502
Blood Adv. 2021 Aug 10;5(15):3016-3020
pubmed: 34351389
Lancet. 2020 Nov 14;396(10262):1563-1573
pubmed: 33189178
Blood Cancer J. 2019 Mar 20;9(4):37
pubmed: 30894515